Abstract
Regional brain atrophy estimated from structural magnetic resonance imaging (MRI) is a widely used measure of neurodegeneration in Alzheimer's disease (AD), Frontotemporal Lobar Degeneration (FTLD), and other dementias. Yet, traditional MRI-derived morphometric estimates are susceptible to measurement errors, posing a challenge for reliably detecting longitudinal atrophy, particularly over short intervals. Here, we examined the utility of multiple MRI scans acquired in rapid succession (i.e., cluster scanning) for detecting longitudinal cortical atrophy over 3- and 6-month intervals within individual patients. Four individuals with mild cognitive impairment or mild dementia likely due to AD or FTLD participated in this study. At baseline, 3 months, and 6 months, structural MRI data were collected on a 3 Tesla scanner using a fast 1.2-mm T1-weighted multi-echo magnetization-prepared rapid gradient echo (MEMPRAGE) sequence (acquisition time = 2'23''). At each timepoint, participants underwent up to 32 MEMPRAGE scans acquired in four separate sessions over two days. Using linear mixed-effects models, phenotypically vulnerable cortical ("core atrophy") regions exhibited statistically significant longitudinal atrophy in all participants (i.e., decreased cortical thickness) by 3 months and further demonstrated preferential vulnerability compared to control regions in three of the participants over at least one of the 3-month intervals. These findings provide proof-of-concept evidence that pooling multiple morphometric estimates derived from cluster scanning can detect longitudinal cortical atrophy over short intervals in individual patients with neurodegenerative dementias.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by US National Institutes of Health (R01 AG081249, R01 DC014296, R01 NS131395, K01 AG084820, R21 AG080588, K23 DC016912, K00 AG068432, P50 AG005134, P30 AG062421), Alzheimer's Association (AARG-24-1309264), and by the Tommy Rickles Chair in Primary Progressive Aphasia Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mass General Brigham Healthcare. gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos